249 related articles for article (PubMed ID: 38675148)
1. Proton-Pump Inhibitors in Eosinophilic Esophagitis: A Review Focused on the Role of Pharmacogenetics.
Rodríguez-Alcolado L; Navarro P; Arias-González L; Grueso-Navarro E; Lucendo AJ; Laserna-Mendieta EJ
Pharmaceutics; 2024 Apr; 16(4):. PubMed ID: 38675148
[TBL] [Abstract][Full Text] [Related]
2. CYP2C19 and STAT6 Variants Influence the Outcome of Proton Pump Inhibitor Therapy in Pediatric Eosinophilic Esophagitis.
Mougey EB; Williams A; Coyne AJK; Gutiérrez-Junquera C; Fernández-Fernández S; Cilleruelo ML; Rayo A; Echeverría L; Román E; González Lois C; Chao M; Al-Atrash H; Lima JJ; Franciosi JP
J Pediatr Gastroenterol Nutr; 2019 Nov; 69(5):581-587. PubMed ID: 31490856
[TBL] [Abstract][Full Text] [Related]
3. Impact of
Soria-Chacartegui P; Navares-Gómez M; Molina-Jiménez F; Laserna-Mendieta EJ; Arias-González L; Majano P; Casabona S; Lucendo AJ; Abad-Santos F; Santander C; Zubiaur P
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612496
[TBL] [Abstract][Full Text] [Related]
4. Proton pump inhibitors in eosinophilic esophagitis (EoE) related to oral immunotherapy: is it as effective as in other EoE?
Shalem T; Cohen DL; Epstein-Rigbi N; Elizur A; Eindor-Abarbanel A; Broide E; Richter V
Eur J Pediatr; 2023 Dec; 182(12):5409-5416. PubMed ID: 37750913
[TBL] [Abstract][Full Text] [Related]
5. Determinant factors for first-line treatment choice and effectiveness in pediatric eosinophilic esophagitis: an analysis of the EUREOS EoE CONNECT registry.
Navarro P; Feo-Ortega S; Casabona-Francés S; Gutiérrez-Junquera C; Savarino EV; Amorena E; Fernández-Fernández S; Pérez-Martínez I; Oliva S; Barrio J; Masiques-Mas ML; Guardiola-Arévalo A; Guagnozzi D; Racca F; Betoré E; Votto M; Rodríguez-Sánchez A; Barrio ML; Blas-Jhon L; Sánchez-Vegazo CT; García-Morales N; Krarup AL; Dainese R; Martín-Dominguez V; García-Díaz A; Maniero D; Santander C; Arias Á; Laserna-Mendieta EJ; Lucendo AJ
Eur J Pediatr; 2024 May; ():. PubMed ID: 38819501
[TBL] [Abstract][Full Text] [Related]
6. Similarities and differences among eosinophilic esophagitis, proton-pump inhibitor-responsive esophageal eosinophilia, and reflux esophagitis: comparisons of clinical, endoscopic, and histopathological findings in Japanese patients.
Jiao D; Ishimura N; Maruyama R; Ishikawa N; Nagase M; Oshima N; Aimi M; Okimoto E; Mikami H; Izumi D; Okada M; Ishihara S; Kinoshita Y
J Gastroenterol; 2017 Feb; 52(2):203-210. PubMed ID: 27108416
[TBL] [Abstract][Full Text] [Related]
7. Eosinophilic esophagitis in Japan: Focus on response to acid suppressive therapy.
Ishimura N; Kinoshita Y
J Gastroenterol Hepatol; 2018 May; 33(5):1016-1022. PubMed ID: 29278655
[TBL] [Abstract][Full Text] [Related]
8. STAT6 Variants Associate With Relapse of Eosinophilic Esophagitis in Patients Receiving Long-term Proton Pump Inhibitor Therapy.
Mougey EB; Nguyen V; Gutiérrez-Junquera C; Fernández-Fernández S; Cilleruelo ML; Rayo A; Borrell B; Román E; González-Lois C; Chao M; Al-Atrash H; Franciosi JP
Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2046-2053.e2. PubMed ID: 32798708
[TBL] [Abstract][Full Text] [Related]
9. Allergic phenotype identified on allergen testing is associated with proton pump inhibitor nonresponse in eosinophilic esophagitis.
Muftah M; Hartnett DA; Flanagan R; Redd WD; Jenkins A; Goldin AH; Hsu Blatman K; Chan WW
J Gastroenterol Hepatol; 2024 Apr; 39(4):701-707. PubMed ID: 38185799
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of PPI treatment and guideline adherence in 236 patients with eosinophilic oesophagitis-Results from the population-based DanEoE cohort shows a low complication rate.
Frandsen LT; Westmark S; Melgaard D; Krarup AL
United European Gastroenterol J; 2021 Oct; 9(8):910-918. PubMed ID: 34477326
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of response to PPI treatment in children and adolescents with eosinophilic esophagitis in southern Brazil.
Nader LS; Epifanio M; Coelho MG; Steinhaus C; Melere M; da Silva CS; Ferreira CT
Front Allergy; 2024; 5():1346843. PubMed ID: 38650863
[TBL] [Abstract][Full Text] [Related]
12. [Proton Pump Inhibitor-responsive Esophageal Eosinophilia: An Overview of Cases from One University Hospital Center].
Ahn B; Lee DH; Lee CM; Hwang JJ; Yoon H; Shin CM; Park YS; Kim N
Korean J Gastroenterol; 2016 Apr; 67(4):178-82. PubMed ID: 27112243
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitor therapy reverses endoscopic features of fibrosis in eosinophilic esophagitis.
Navarro P; Laserna-Mendieta EJ; Guagnozzi D; Casabona S; Perelló A; Savarino E; de la Riva S; Olalla JM; Ghisa M; Serrano-Moya N; Alcolea-Valero C; Ortega-Rabbione G; Majano P; Santander C; Arias Á; Lucendo AJ;
Dig Liver Dis; 2021 Nov; 53(11):1479-1485. PubMed ID: 34120859
[TBL] [Abstract][Full Text] [Related]
14. Eosinophilic esophagitis and proton pump inhibitors: controversies and implications for clinical practice.
Asher Wolf W; Dellon ES
Gastroenterol Hepatol (N Y); 2014 Jul; 10(7):427-32. PubMed ID: 25904830
[TBL] [Abstract][Full Text] [Related]
15. Optimal Biopsy Protocol to Evaluate Histological Effectiveness of Proton Pump Inhibitor Therapy in Patients with Eosinophilic Esophagitis.
Fujiwara Y; Hashimoto A; Uemura R; Sawada A; Otani K; Tanaka F; Yamagami H; Tanigawa T; Watanabe T; Kabata D; Kuwae Y; Shintani A; Ohsawa M
Digestion; 2019; 100(1):64-71. PubMed ID: 30408792
[TBL] [Abstract][Full Text] [Related]
16. Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis.
Molina-Infante J; Bredenoord AJ; Cheng E; Dellon ES; Furuta GT; Gupta SK; Hirano I; Katzka DA; Moawad FJ; Rothenberg ME; Schoepfer A; Spechler SJ; Wen T; Straumann A; Lucendo AJ;
Gut; 2016 Mar; 65(3):524-31. PubMed ID: 26685124
[TBL] [Abstract][Full Text] [Related]
17. Circulating immunome fingerprint in eosinophilic esophagitis is associated with clinical response to proton pump inhibitor treatment.
Ugalde-Triviño L; Molina-Jiménez F; H-Vázquez J; Relaño-Rupérez C; Arias-González L; Casabona S; Pérez-Fernández MT; Martín-Domínguez V; Fernández-Pacheco J; Lucendo AJ; Bernardo D; Santander C; Majano P
Front Immunol; 2024; 15():1374611. PubMed ID: 38646544
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of filaggrin is decreased in proton pump inhibitor non-responders compared with proton pump inhibitor responders of eosinophilic esophagitis.
Nagano N; Araki A; Ishikawa N; Nagase M; Adachi K; Ishimura N; Ishihara S; Kinoshita Y; Maruyama R
Esophagus; 2021 Apr; 18(2):362-371. PubMed ID: 32909083
[TBL] [Abstract][Full Text] [Related]
19. Proton pump inhibitors partially restore mucosal integrity in patients with proton pump inhibitor-responsive esophageal eosinophilia but not eosinophilic esophagitis.
van Rhijn BD; Weijenborg PW; Verheij J; van den Bergh Weerman MA; Verseijden C; van den Wijngaard RM; de Jonge WJ; Smout AJ; Bredenoord AJ
Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1815-23.e2. PubMed ID: 24657840
[TBL] [Abstract][Full Text] [Related]
20. PPI-responsive esophageal eosinophilia cannot be distinguished from eosinophilic esophagitis by endoscopic signs.
Warners MJ; van Rhijn BD; Curvers WL; Smout AJ; Bredenoord AJ
Eur J Gastroenterol Hepatol; 2015 May; 27(5):506-11. PubMed ID: 25822858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
